Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 7/20 | 0.66 |
| ▸ | MAOB | P27338 | 7/20 | 0.66 |
| ▸ | NPC1 | O15118 | 6/20 | 0.58 |
| ▸ | RAB9A | P51151 | 6/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | SRC | P12931 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | TLR4 | O00206 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CDK4 | P11802 | 1/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.46 |
| ▸ | CCND1 | P24385 | 1/20 | 0.46 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15426822 | 0.94 | MAOA (0.60) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL22181586 | 0.94 | MAOA (0.60) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL9059700 | 0.94 | MAOA (0.70) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL30724528 | 0.94 | MAOA (0.64) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL8716037 | 0.92 | MAOA (0.62) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL8374655 | 0.92 | MAOA (0.62) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL8374654 | 0.92 | MAOA (0.62) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL30855377 | 0.91 | NPC1 (0.59) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL1279355 | 0.91 | NPC1 (0.59) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL3575088 | 0.89 | MAOA (0.58) | MAOAMAOBNPC1RAB9ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1309253-B1 | METHODS AND DEVICES FOR REMOVING NUCLEOPHILIC TOXINS FROM TOBACCO AND TOBACCO SMOKE | CERAMI CONSULTING CORP (US) | 2007-05-23 | — | — | EP | claimed |
| US-6615842-B1 | Methods for removing nucleophilic toxins from tobacco smoke | CERAMI CONSULTING CORP. | 2003-09-09 | — | — | US | claimed |
| EP-1309253-A1 | METHODS, AGENTS AND DEVICES FOR REMOVING NUCLEOPHILIC TOXINS FROM TOBACCO AND TOBACCO SMOKE | Cerami Consulting Corporation (US) | 2003-05-14 | — | — | EP | claimed |
| WO-2002000046-A1 | METHODS, AGENTS AND DEVICES FOR REMOVING NUCLEOPHILIC TOXINS FROM TOBACCO AND TOBACCO SMOKE | CERAMI CONSULTING CORP. (US) | 2002-01-03 | — | — | WO | claimed |
| US-9550845-B2 | Multiple stage curable polymer with controlled transitions | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160264695-A1 | MULTIPLE STAGE CURABLE POLYMER WITH CONTROLLED TRANSITIONS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-09-15 | — | — | US | disclosed |
| EP-1309253-B1 | METHODS AND DEVICES FOR REMOVING NUCLEOPHILIC TOXINS FROM TOBACCO AND TOBACCO SMOKE | CERAMI CONSULTING CORP (US) | 2007-05-23 | — | — | EP | disclosed |
| EP-1160240-B1 | Guanylhydrazones for treating inflammatory conditions | CYTOKINE PHARMASCIENCES INC (US) | 2006-11-22 | — | — | EP | disclosed |
| US-6615842-B1 | Methods for removing nucleophilic toxins from tobacco smoke | CERAMI CONSULTING CORP. | 2003-09-09 | — | — | US | disclosed |
| EP-1309253-A1 | METHODS, AGENTS AND DEVICES FOR REMOVING NUCLEOPHILIC TOXINS FROM TOBACCO AND TOBACCO SMOKE | Cerami Consulting Corporation (US) | 2003-05-14 | — | — | EP | disclosed |
| EP-0746312-B1 | GUANYLHYDRAZONES FOR TREATING INFLAMMATORY CONDITIONS | PICOWER INST MED RES (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020028851-A1 | Aromatic guanylhydrazones (amidinohydrazones) used to prevent and ameliorating cachexia; to inhibit the uptake of arginine by macrophages and/or its conversion to urea; to prevent the generation of nitric oxide (NO) and tumor necrosis factor | BIANCHI MARINA (IT) | 2002-03-07 | — | — | US | disclosed |
| US-5859062-A | ADMINISTERING TO TREAT INFLAMMATORY DISEASES MEDIATED BY TUMOR NECROSIS FACTOR | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1999-01-12 | — | — | US | disclosed |
| US-5854289-A | Guanylhydrazones and their use to treat inflammatory conditions | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-12-29 | — | — | US | disclosed |
| US-5849794-A | Guanylhydrazones and their use to treat inflammatory conditions | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-12-15 | — | — | US | disclosed |
| US-5753684-A | Guanylhydrazones and their use to treat inflammatory conditions | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-05-19 | — | — | US | disclosed |
| US-5750573-A | PREVENTING AND TREATING CACHEXIA, THE CLINICAL SYNDROME OF POOR NUTRITION AND BODILY WASTING ASSOCIATED WITH CANCER AND CHRONIC DISEASES; ARGINASE INHIBITORS | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-05-12 | — | — | US | disclosed |
| US-5599984-A | AROMATIC AMIDINOHYDRAZONES AS INHIBITORS FOR THE UPTAKE OF ARGININE BY MACROPHAGES AND/OR ITS CONVERSION TO UREA; PREVENTION OF NITRIC OXIDE GENERATION; CACHEXIA; METABOLIC SYNDROMES | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1997-02-04 | — | — | US | disclosed |
| EP-0746312-A1 | GUANYLHYDRAZONES FOR TREATING INFLAMMATORY CONDITIONS | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1996-12-11 | — | — | EP | disclosed |
| WO-1995019767-A1 | GUANYLHYDRAZONES FOR TREATING INFLAMMATORY CONDITIONS | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1995-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028851-A1 | Aromatic guanylhydrazones (amidinohydrazones) used to prevent and ameliorating cachexia; to inhibit the uptake of arginine by macrophages and/or its conversion to urea; to prevent the generation of nitric oxide (NO) and tumor necrosis factor | ARG1, ARG2, NOS3 | MAOA 2553/4885MAOB 2301/4885NPC1 3888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.